Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158145 · ClinicalTrials.gov registry record
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 72
- Enrollment target
NCT00158145 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 72 participants.
The verdict
NCT00158145 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
Study Summary
Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens. Biomarkers that quantify carcinogen levels and metabolism are a useful tool and available to use. The purpose of this study is to assess the variability of tobacco smoke carcinogen biomarker levels over one year in a group of smokers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158145
The ClinicalTrials.gov registry entry for NCT00158145 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00158145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00158145 about?
NCT00158145 is a clinical study titled "Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2". Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens. Biomarkers that quantify carcinogen levels and metabolism are a useful tool and a...
What is the current status of trial NCT00158145?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2005-09. Estimated completion is 2007-04.
Who is sponsoring clinical trial NCT00158145?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.